 |
| (Source: Boehringer Ingelheim) |
Five South Korean pharmaceutical companies have petitioned the Intellectual Property Trial and Appeal Board to invalidate a Boehringer Ingelheim International GmbH patent covering therapeutic uses of the diabetes drug empagliflozin.
The invalidation petitions, filed between February and April 2024, target Korean Patent No. 2318207, titled "Therapeutic Uses of Empagliflozin." The challengers include Chong Kun Dang Pharmaceutical Corp., Genuone Sciences Inc., Korea Prime Pharm. Co. Ltd., Hanmi Pharm. Co. Ltd., and Huons Co. Ltd.
The patent discloses the use of SGLT-2 inhibitors such as empagliflozin for the treatment and prevention of oxidative stress in patients with type 1 or type 2 diabetes, as well as for the treatment and prevention of cardiovascular disease in those patients. It further claims methods for addressing metabolic disorders, reducing the risk of cardiovascular events, and delaying their onset in diabetic patients.
By PatenTrip
Comments
Post a Comment